Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Katsuyo Ohashi‐Doi"'
Autor:
Akira Saito, Toshiyuki Koya, Ami Aoki, Shun Naramoto, Hiroshi Ueno, Yuki Nishiyama, Kenjiro Shima, Yosuke Kimura, Takashi Hasegawa, Satoshi Watanabe, Yasuyoshi Ohshima, Keisuke Suzuki, Katsuyo Ohashi-Doi, Toshiaki Kikuchi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Sublingual immunotherapy (SLIT) has received considerable attention as a method for allergen immunotherapy (AIT). However, the mechanism of SLIT, especially its timing, has not been thoroughly investigated. We evaluated therapeutic and proph
Externí odkaz:
https://doaj.org/article/fd44cc5a7c2948bdbfcbaa10a6749b99
Autor:
Yoshiaki Kobayashi, MD, Keisuke Suzuki, MSc, Minoru Tateno, PhD, Yuki Nakamura, PhD, Kayoko Ishimaru, Yuka Nagasaka, Daiju Sakurai, MD, PhD, Katsuyo Ohashi-Doi, PhD, Atsuhito Nakao, MD, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 1, Pp 100198- (2024)
Background: In Japan, pollinosis caused by the Japanese cypress (JCy) Chamaecyparis obtusa is among the very common seasonal allergies. In JCy pollinosis, Cha o 1 is the first major allergen, and Cha o 2 is the second major allergen. Recently, Cha o
Externí odkaz:
https://doaj.org/article/6df5c98618d94ef0b6a99fe1f43d8ca0
Publikováno v:
Allergology International, Vol 71, Iss 3, Pp 405-408 (2022)
Externí odkaz:
https://doaj.org/article/20dc9926230645eba19991a296466024
Autor:
Masatoshi Abe, Hajime Iizuka, Ikue Nemoto‐Hasebe, Osamu Nemoto, Hiroyuki Toyama, Katsuyo Ohashi‐Doi, Kenji Kabashima
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 5, Iss 2, Pp 38-46 (2022)
Abstract Objectives Delgocitinib is a small‐molecule JAK inhibitor that has recently been approved in Japan as the world's first topical JAK/STAT pathway inhibitor for the treatment of atopic dermatitis (AD). In this study, the effects of delgociti
Externí odkaz:
https://doaj.org/article/1b230c2a967044cfbe188f40810d7916
Autor:
Takashi Kanno, Yoshiyuki Adachi, Katsuyo Ohashi-Doi, Hiroki Matsuhara, Rie Hiratsuka, Ken-ichi Ishibashi, Daisuke Yamanaka, Naohito Ohno
Publikováno v:
Allergology International, Vol 70, Iss 1, Pp 105-113 (2021)
Background: The pollen grains of several plant species contain 1,3-β-D-glucan (BG). BG activates dendritic cells (DCs) and subsequently regulates the innate immune responses. Within Japan, the most common disease associated with type-I hypersensitiv
Externí odkaz:
https://doaj.org/article/95ce7fa36cdd4934ba36207682c24dc9
Autor:
Mamiko Morinaga, Haruyo Nakajima-Adachi, Erika Hiraide, Noriko Kitamura, Osamu Kaminuma, Takachika Hiroi, Katsuyo Ohashi-Doi, Satoshi Hachimura
Publikováno v:
Allergology International, Vol 69, Iss 4, Pp 622-625 (2020)
Externí odkaz:
https://doaj.org/article/746a6014a0ec45deab9543c1f04bca7d
Autor:
Takashi Yamamoto, PhD, Katsuyo Ohashi-Doi, PhD, Hiroki Matsuhara, BSc, Loes Verhoog, MSc, Morten Lindholm, PhD, Simon Lawton, MD, Kaare Lund, PhD
Publikováno v:
Current Therapeutic Research, Vol 96, Iss , Pp 100678- (2022)
ABSTRACT: Background: Sublingual allergy immunotherapy tablets (SLIT-tablets) provide a well-tolerated and clinically efficacious treatment for allergic disease such as allergic rhinitis and allergic asthma. In SLIT, uptake of allergen by immune-comp
Externí odkaz:
https://doaj.org/article/a76e3aeb592e4918afe6b8172ba408d3
Autor:
Katsuyo Ohashi-Doi, Kaare Lund, Henrik Ipsen, Peter Sejr Andersen, Holger Mosbech, J. Christian Virchow, Minoru Kudo, Thomas Stranzl, Tomokazu Matsuoka
Publikováno v:
Allergology International, Vol 69, Iss 2, Pp 281-283 (2020)
Externí odkaz:
https://doaj.org/article/8ea51a54ca334173b3b86d25995667b1
Autor:
Chiharu Fukano, Katsuyo Ohashi-Doi, Kaare Lund, Atsuhito Nakao, Keisuke Masuyama, Tomokazu Matsuoka
Publikováno v:
Journal of Pharmacological Sciences, Vol 140, Iss 3, Pp 223-227 (2019)
Background: Clinical efficacy of allergen-specific Immunotherapy (AIT) towards Japanese cedar (JC) pollen allergy is firmly established but JC pollen-specific biomarker assays are lacking. Treatment-related increase of allergen-specific antibodies is
Externí odkaz:
https://doaj.org/article/e98a28205f894e88be8633295c7bdc8d
Publikováno v:
Allergology International, Vol 66, Iss 3, Pp 432-439 (2017)
Background: Allergen-specific sublingual immunotherapy is a potential disease-modifying treatment for allergic asthma. Galectin-9 (Gal-9), a β-galactoside-binding protein with various biologic effects, acts as an immunomodulator in excessive immunol
Externí odkaz:
https://doaj.org/article/35ae6be3c4d445e8b8a54802ed23574d